CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. Chunghwa Chemical Synthesis & Biotech Co., Ltd. Share Price
Equities
1762
TW0001762003
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 46.15 TWD | +0.65% |
|
+2.67% | -19.60% |
| Sales 2024 * | 1.73B 53.43M 4.26B | Sales 2025 * | - | Capitalization | 3.59B 111M 8.85B |
|---|---|---|---|---|---|
| Net income 2024 * | 207M 6.39M 510M | Net income 2025 * | - | EV / Sales 2024 * | 2.08 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
17.2
x | P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.09% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.65% | ||
| 1 week | +2.67% | ||
| Current month | -5.53% | ||
| 1 month | -5.53% | ||
| 3 months | -11.42% | ||
| 6 months | -15.48% | ||
| Current year | -19.60% |
1 week
44.85
46.20
1 month
43.6049.50
Current year
43.6058.20
1 year
43.60102.50
3 years
43.60102.50
5 years
23.85102.50
10 years
20.05102.50
| Managers | Title | Age | Since |
|---|---|---|---|
Chung Hsin Huang
CEO | Chief Executive Officer | - | 28/12/09 |
Chun-Ming Chen
CTO | Chief Tech/Sci/R&D Officer | - | 12/02/17 |
Kuan-Chieh Wang
IRO | Public Communications Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yin Nan Sun
BRD | Director/Board Member | - | 11/05/98 |
Cheng Hsien Tsai
BRD | Director/Board Member | - | 19/06/12 |
Chung Hsin Huang
CEO | Chief Executive Officer | - | 28/12/09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/05/24 | 46.3 | +0.33% | 109,601 |
| 30/04/24 | 46.15 | +0.65% | 217,258 |
| 29/04/24 | 45.85 | +2.12% | 202,289 |
| 26/04/24 | 44.9 | -.--% | 156,181 |
| 25/04/24 | 44.9 | -0.55% | 112,879 |
End-of-day quote Taiwan S.E., April 29, 2024
More quotes
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
Sector
Pharmaceuticals
Calendar
29/05/2024
- Annual General Meeting
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
46.3
TWD
Average target price
48
TWD
Spread / Average Target
+3.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.60% | 110M | |
| -3.93% | 86.16B | |
| +2.76% | 40.17B | |
| -17.23% | 31.47B | |
| +54.44% | 25.24B | |
| -11.95% | 15.82B | |
| -9.12% | 11.96B | |
| -15.51% | 11.89B | |
| -42.56% | 11.61B | |
| +4.87% | 8.84B |
- Stock Market
- Equities
- 1762 Stock
